Drugs / CLZ-2002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05947578 | Jun 2023 → Aug 2024 | Charcot-Marie-Tooth disease type 1 | Cellatoz Therapeutics, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLZ-2002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05947578 ↗ |
| Route | Intramuscular | “CLZ-2002 injection is intramuscular in lower limbs on Day 1.” NCT05947578 ↗ |